Adjuvant platinum-based chemotherapy for borderline serous ovarian tumors with invasive implants

Gynecologic Oncology

Volumn 132, Issue 1, 2014, Pages 23-27

  Leary, Alexandra ^a   Petrella, Marie Christina ^a   Pautier, Patricia ^a   Duvillard, Pierre ^a   Uzan, Catherine ^a   Tazi, Youssef ^a   Ledoux, Florence ^a   Gouy, Sébastien ^a   Morice, Philippe ^a   Lhommé, Catherine ^a  

^a Gynecology Unit   (France)

Author keywords

Adjuvant chemotherapy; Invasive implants; Serous borderline ovarian tumor

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; IFOSFAMIDE; PACLITAXEL; TAXANE DERIVATIVE;

ABDOMINAL HYSTERECTOMY; ARTICLE; BORDERLINE OVARY TUMOR; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURGERY; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; MULTIPLE CYCLE TREATMENT; OVARY TUMOR; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SALPINGOOOPHORECTOMY; TUMOR INVASION; UNSPECIFIED SIDE EFFECT;

ADJUVANT CHEMOTHERAPY; INVASIVE IMPLANTS; SEROUS BORDERLINE OVARIAN TUMOR;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PLATINUM; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84892808121     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.11.006     Document Type: Article

References (26)

1. F.A. Tavassoli DPWHO: tumours of the breast and female genital organs in press I (ed): pathology and genetics 2003 the international agency for research on cancer Lyon
2. U. Elchalal, R. Dgani, and B. Piura et al. Current concepts in management of epithelial ovarian tumors of low malignant potential Obstet Gynecol Surv 50 1995 62 70
3. C.W. Burger, H.M. Prinssen, and J.P. Baak et al. The management of borderline epithelial tumors of the ovary Int J Gynecol Cancer 10 2000 181 197
4. N.B.K. De Gregorio, M.D. Keyver-Paik, A. Reuss, U. Canzler, K. Wollschlaeger, and F. Kommoss et al. Outcome of patients with borderline ovarian tumors: results of the multicenter AGO ROBOT study J Clin Oncol 30 2012 5005
5. D.A. Bell, M.A. Weinstock, and R.E. Scully Peritoneal implants of ovarian serous borderline tumors. Histologic features and prognosis Cancer 62 1988 2212 2222
6. J.C. Bendell, J. Rodon, and H.A. Burris et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors J Clin Oncol 30 2012 282 290
7. K.A. Bell, A.E. Smith Sehdev, and R.J. Kurman Refined diagnostic criteria for implants associated with ovarian atypical proliferative serous tumors (borderline) and micropapillary serous carcinomas Am J Surg Pathol 25 2001 419 432
8. D.A. Bell, T.A. Longacre, and J. Prat et al. Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives Hum Pathol 35 2004 934 948
9. R.T. Burks, M.E. Sherman, and R.J. Kurman Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors Am J Surg Pathol 20 1996 1319 1330
10. J.D. Seidman, and R.J. Kurman Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases Am J Surg Pathol 20 1996 1331 1345
11. O. Faluyi, M. Mackean, and C. Gourley et al. Interventions for the treatment of borderline ovarian tumours Cochrane Database Syst Rev 2010 CD007696
12. K.K. Shih, Q.C. Zhou, and C. Aghajanian et al. Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors Gynecol Oncol 119 2010 270 273
13. P. Morice, S. Camatte, and R. Rouzier et al. Prognostic factors and treatment for advanced-stage borderline ovarian tumors J Gynecol Obstet Biol Reprod (Paris) 31 2002 623 628
14. J.D. Seidman, and R.J. Kurman Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators Hum Pathol 31 2000 539 557
15. P. Morice, C. Uzan, and R. Fauvet et al. Borderline ovarian tumour: pathological diagnostic dilemma and risk factors for invasive or lethal recurrence Lancet Oncol 13 2012 e103 e115
16. D.M. Gershenson, E.G. Silva, and L. Levy et al. Ovarian serous borderline tumors with invasive peritoneal implants Cancer 82 1998 1096 1103
17. G. Zanetta, S. Rota, and S. Chiari et al. Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study J Clin Oncol 19 2001 2658 2664
18. R.J. Kurman, and C.L. Trimble The behavior of serous tumors of low malignant potential: are they ever malignant? Int J Gynecol Pathol 12 1993 120 127
19. A. Kane, C. Uzan, and A. Rey et al. Prognostic factors in patients with ovarian serous low malignant potential (borderline) tumors with peritoneal implants Oncologist 14 2009 591 600
20. D.M. Gershenson, E.G. Silva, and G. Tortolero-Luna et al. Serous borderline tumors of the ovary with noninvasive peritoneal implants Cancer 83 1998 2157 2163
21. K.K. Shih, Q. Zhou, and J. Huh et al. Risk factors for recurrence of ovarian borderline tumors Gynecol Oncol 120 2011 480 484
22. T.A. Longacre, R.L. Kempson, and M.R. Hendrickson Serous tumours of low malignant potential (serous borderline tumours): moving toward detente Histopathology 47 2005 315 318
23. M.A. Crispens, D. Bodurka, and M. Deavers et al. Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential Obstet Gynecol 99 2002 3 10
24. R. Yazigi, A.K. Munoz, and J. Sandstad et al. Cisplatin based combination chemotherapy in the treatment of stage III ovarian epithelial tumors of low malignant potential Eur J Gynaecol Oncol 12 1991 451 455
25. K. Anzai, E. Sekine-Suzuki, and M. Ueno et al. Effectiveness of combined treatment using X-rays and a phosphoinositide 3-kinase inhibitor, ZSTK474, on proliferation of HeLa cells in vitro and in vivo Cancer Sci 102 2011 1176 1180
26. J. Farley, W.E. Brady, and V. Vathipadiekal et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study Lancet Oncol 14 2013 134 140